Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7000380 | 0.88 | ALDH1A1 (0.59) | ALDH1A1MAPK1POLBSMN1; SMN2CDK1 | |
| SCHEMBL7000701 | 0.88 | SMN1; SMN2 (0.64) | ALDH1A1MAPK1POLBSMN1; SMN2CDK1 | |
| SCHEMBL12505394 | 0.87 | ALDH1A1 (0.57) | ALDH1A1MAPK1POLBSMN1; SMN2CDK1 | |
| SCHEMBL1493992 | 0.86 | MAPK1 (0.57) | ALDH1A1MAPK1POLBSMN1; SMN2RORC | |
| SCHEMBL10033006 | 0.85 | ALDH1A1 (0.63) | ALDH1A1MAPK1POLBSMN1; SMN2CDK1 | |
| SCHEMBL3833657 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MAPK1POLBSMN1; SMN2KCNK3 | |
| SCHEMBL1851780 | 0.84 | SMN1; SMN2 (0.68) | ALDH1A1MAPK1POLBSMN1; SMN2HTT | |
| SCHEMBL30492996 | 0.84 | SMN1; SMN2 (0.68) | ALDH1A1MAPK1POLBSMN1; SMN2HTT | |
| SCHEMBL7563176 | 0.82 | LMNA (0.61) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL5952099 | 0.81 | ALDH1A1 (0.62) | ALDH1A1MAPK1POLBSMN1; SMN2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727803-B3 | PROCESSES FOR PREPARING SUBSTITUTED N-ARYL-N'-[3-(1H-PYRAZOL-5-YL)PHENYL] UREAS AND INTERMEDIATES THEREOF | ARENA PHARM INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-1727803-B3 | PROCESSES FOR PREPARING SUBSTITUTED N-ARYL-N'-[3-(1H-PYRAZOL-5-YL)PHENYL] UREAS AND INTERMEDIATES THEREOF | ARENA PHARM INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-1727803-B1 | PROCESSES FOR PREPARING SUBSTITUTED N-ARYL-N'-[3-(1H-PYRAZOL-5-YL)PHENYL] UREAS AND INTERMEDIATES THEREOF | ARENA PHARM INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7812176-B2 | reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812176-B2 | reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812176-B2 | reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070293685-A1 | reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293685-A1 | reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293685-A1 | reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1727803-A1 | PROCESSES FOR PREPARING SUBSTITUTED N-ARYL-N'-[3-(1H-PYRAZOL-5-YL)PHENYL] UREAS AND INTERMEDIATES THEREOF | Arena Pharmaceuticals, Inc. (US) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005103011-A1 | PROCESSES FOR PREPARING SUBSTITUTED N-ARYL-N’-[3-(1H-PYRAZOL-5-YL) PHENYL] UREAS AND INTERMEDIATES THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-6096766-A | 3-benzylaminopiperidines as tachykinin receptor antagonists | MERCK SHARP & DOHME LTD. (GB) | 2000-08-01 | — | — | US | disclosed |
| EP-0866790-A1 | 3-BENZYLAMINOPYRROLIDINES AND -PIPERIDINES AS TACHYKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997021702-A1 | 3-BENZYLAMINOPYRROLIDINES AND -PIPERIDINES AS TACHYKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293685-A1 | reacting hydrazone containing compound with isocyanate compound, deprotecting, halogenating; cyclization; 5-HT2A serotonin receptor modulators | HTR5A, HTR2C, HTR2A | ALDH1A1 675/4885MAPK1 2331/4885POLB 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.